Results 291 to 300 of about 176,389 (357)
Some of the next articles are maybe not open access.
Epidemiology and risk-stratification of NAFLD-associated HCC
Journal of Hepatology, 2021NAFLD is projected to become the leading cause of HCC in many countries. Many risk factors for NAFLD are also independently associated with HCC, including obesity, diabetes, Hispanic ethnicity and genetic polymorphisms in PNPLA3, TM6SF2, GCKR, MBOAT7 and
George Ioannou
exaly +2 more sources
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
The Lancet Gastroenterology and Hepatology, 2022BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and the leading cause of liver-related morbidity and mortality. We aimed to predict the burden of NAFLD by examining and estimating the temporal trends of its
K. Riazi +9 more
semanticscholar +1 more source
2019 global NAFLD prevalence - A systematic review and meta-analysis.
Clinical Gastroenterology and Hepatology, 2021BACKGROUND & AIMS The increasing rates of obesity and type 2 diabetes mellitus may lead to increased prevalence of NAFLD. We aimed to determine the current and recent trends on the global and regional prevalence of NAFLD. METHODS Systematic search from
M. Le +30 more
semanticscholar +1 more source
Journal of Hepatology, 2019
BACKGROUND AND AIMS Although Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH) and NASH with advanced fibrosis are closely associated with type 2 diabetes mellitus (T2DM), their global prevalence rates have not been not well
Z. Younossi +9 more
semanticscholar +1 more source
BACKGROUND AND AIMS Although Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH) and NASH with advanced fibrosis are closely associated with type 2 diabetes mellitus (T2DM), their global prevalence rates have not been not well
Z. Younossi +9 more
semanticscholar +1 more source
Digestive Diseases and Sciences, 2022
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years ...
Mahak Chauhan +2 more
openaire +2 more sources
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years ...
Mahak Chauhan +2 more
openaire +2 more sources
Nature Reviews Gastroenterology & Hepatology, 2013
NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority ...
Quentin M, Anstee, Christopher P, Day
openaire +2 more sources
NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority ...
Quentin M, Anstee, Christopher P, Day
openaire +2 more sources
Food & Function, 2021
Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disease. Dietary supplementation has become a promising strategy for managing NAFLD.
Jing-Da Li +6 more
semanticscholar +1 more source
Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disease. Dietary supplementation has become a promising strategy for managing NAFLD.
Jing-Da Li +6 more
semanticscholar +1 more source
Autophagy, NAFLD and NAFLD-Related HCC
2018Non-alcoholic fatty liver disease (NAFLD) will become a dominant cause of hepatocellular carcinoma (HCC) in the coming decade. Whereas the exact molecular mechanisms underlying the progression from simple steatosis, through steatohepatitis, to HCC remains largely unclear, emerging evidence has supported a central role of defective autophagy in the ...
William K K, Wu +2 more
openaire +2 more sources
PNPLA3 and obesity: a synergistic relationship in NAFLD
Nature Reviews Gastroenterology & Hepatology, 2017NAFLD, the hepatic manifestation of the metabolic syndrome, is a multifactorial condition — environmental factors influence an inherited genetic risk. Stender et al. now describe the additive effect of obesity and NAFLD-associated genetic polymorphisms on steatosis, elevated serum alanine aminotransferase levels and cirrhosis, remarkably illustrating ...
Mann JP, Anstee QM
openaire +3 more sources
Scandinavian Journal of Gastroenterology, 2021
Dear Editor,I have read the research article entitled ‘Etiologies and outcomes of cirrhosis in a large contemporary cohort’ by Hagstrom et al. [1].
openaire +2 more sources
Dear Editor,I have read the research article entitled ‘Etiologies and outcomes of cirrhosis in a large contemporary cohort’ by Hagstrom et al. [1].
openaire +2 more sources